Development of an Optimal Approach to Return of Results for Next-generation Sequencing for Prenatal Diagnosis

Development of an Optimal Approach to Return of Results for Families Undergoing Next-generation Sequencing for Prenatal Diagnosis.

To gain knowledge about how patients undergoing prenatal diagnosis for a fetal abnormality understand and react to Whole Genome Sequencing (WGS) testing, so that the investigators can develop more ethical and responsible approach to patient education, counseling, and return of results for patients.

Study Overview

• Status: Withdrawn
• Conditions: Major Fetal Anomaly
• Intervention / Treatment: Procedure: Amniocentesis; Other: Psychosocial assessment; Genetic: Whole Genome Sequencing

Detailed Description

Although whole exome sequencing (WES) was first used for identification of the genetic cause of a disease only in 2009 and whole genome sequencing (WGS) in 2010, and questions remain about their performance as clinical tests, they are already being offered to patients and doctors as a clinical test by several laboratories certified by the US government (14 labs for WES and 5 labs for WGS). The results from WES and WGS can be complex and confusing, even for doctors and scientists who work with this technology on a daily basis; for patients, the process of deciding whether to have WES or WGS testing, undergoing the testing, receiving the results, and trying to use the results for further decision-making could be quite stressful. Currently, this process occurs in an unstandardized fashion, with some patients receiving extensive education and counseling, and others receiving almost none. There is a critical need to identify patient needs and desires in this area, and to develop strategies to satisfy them. The primary goal of this project is to gain knowledge about how patients undergoing prenatal diagnosis for a fetal abnormality understand and react to WGS testing, so that we can develop a more ethical and responsible approach to patient education, counseling, and return of results for patients . In order to do this, we need to evaluate parents' understanding of the utility and limitations of the technology, parents' preferences regarding the types of results they want to receive, and the psychological impact of receiving results from this technology. We will enroll 30 families consisting of a woman carrying a fetus with a major abnormality identified by ultrasound, and the father of the fetus, who have opted for amniocentesis for standard prenatal diagnostic testing (karyotyping, fluorescence in situ hybridization (FISH) and/or microarray testing). Half of the families will serve as controls, who will only have standard prenatal diagnostic testing. For the other half of the families, WGS will be performed in addition to standard diagnostic testing. For all 30 cases, we will perform psychosocial evaluations (including assessments of the subjects' mood, understanding of the technology and preferences for return of results) at the time of enrollment, at the time of return of CLIA-certified genetic testing results (karyotype, FISH, microarray, and/or WGS), and after completion of the pregnancy. In this way, we will learn whether participants are receiving adequate education about next-generation sequencing to make informed choices, what the range of preferences are for return of results in a prenatal population (and whether this changes when new methods for prenatal diagnosis are employed), and whether the use of WGS imposes additional psychological stress compared to standard prenatal diagnostic tests. This study will be carried out in a stepwise and carefully monitored environment, with progress overseen by an Independent Data Monitoring Committee in order to maximize the knowledge gained while minimizing potential harms.

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • San Diego, California, United States, 92121
      • UCSD Health Sciences, Fetal Care and Genetics

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject(s) 18 years or older (both mom and father of baby (FOB)
• Subject is undergoing prenatal testing for a major fetal anomaly

Exclusion Criteria:

• Mothers or fathers of the affected fetus are under the age of 18 years

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Control Group; Amniocentesis will be performed, Whole Genome Sequencing will not be performed, and psychosocial assessment will be performed.	Procedure: Amniocentesis; Note: this is being performed on all subjects as a clinical (not research) procedure; Other: Psychosocial assessment; Use of EPDS and STAI for assessment of maternal and paternal mood
Experimental: Intervention Group; Amniocentesis will be performed, Whole Genome Sequencing will be performed if the karyotype is normal, and psychosocial assessment will be performed.	Procedure: Amniocentesis; Note: this is being performed on all subjects as a clinical (not research) procedure; Other: Psychosocial assessment; Use of EPDS and STAI for assessment of maternal and paternal mood; Genetic: Whole Genome Sequencing; Whole genome sequencing in a CLIA lab and return of results.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in maternal mood (focused on assessment of depression)	Compare mood measured by EPDS between enrollment and 3 months after completion of pregnancy	At enrollment and 3 months after completion of pregnancy (expected to be 8 months after enrollment)
Change in paternal mood (focused on assessment of depression)	Compare mood measured by EPDS between enrollment and 3 months after completion of pregnancy	At enrollment and 3 months after completion of pregnancy (expected to be 8 months after enrollment)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in maternal mood (focused on assessment of anxiety)	Compare anxiety measured by STAI between enrollment and 3 months after completion of pregnancy	At enrollment and 3 months after completion of pregnancy (expected to be 8 months after enrollment)
Change in paternal mood (focused on assessment of anxiety)	Compare anxiety measured by STAI between enrollment and 3 months after completion of pregnancy	At enrollment and 3 months after completion of pregnancy (expected to be 8 months after enrollment)

Collaborators and Investigators

• Sponsor: University of California, San Diego

Study record dates

Study Major Dates

• Study Start: October 1, 2014
• Primary Completion (Actual): June 4, 2019
• Study Completion (Actual): June 4, 2019

Study Registration Dates

• First Submitted: September 24, 2014
• First Submitted That Met QC Criteria: September 30, 2014
• First Posted (Estimate): October 3, 2014

Study Record Updates

• Last Update Posted (Actual): June 6, 2019
• Last Update Submitted That Met QC Criteria: June 4, 2019
• Last Verified: June 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Congenital Abnormalities
• Other Study ID Numbers: 140456